GlassScriptPhysician profile
Loren B Betteridge
NPI 1023015211
$12,310.08
in general payments reported to CMS, 2019-2025
46 companies · $858 in 2025
The $858 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $1,301 · 2021: $2,243 · 2022: $2,172 · 2023: $1,952 · 2024: $2,400 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,178 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,177.77 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,115.79 | 2019-2025 | Ubrelvy, Linzess, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,443.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,149.26 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $1,039.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $927.73 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $816.21 | 2019-2025 | |
| Lilly USA, LLC | $638.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $576.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $413.87 | 2019-2023 | Xarelto |
| Daiichi Sankyo INC. | $260.93 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $231.41 | 2019-2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $222.45 | 2020-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $208.81 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $206.12 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $195.81 | 2022-2025 | Zoryve, Seglentis, Livalo |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loren Betteridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.